{"success":true,"data":{"pressRelease":{"id":"90686","rtpr_id":"nPnbNyhzna","ticker":"GRAL","exchange":"NASDAQ","all_tickers":["GRAL"],"title":"GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline","author":"PR Newswire","published_at":"2026-07-16T14:09:00.831Z","article_body":"GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline\n\nPR Newswire\n\nNEW YORK, July 16, 2026\n\nTime-Sensitive: Allegations Focus on Defendants' Refusal to Share Detailed\nNHS-Galleri Data, Potentially Concealing Adverse Trendlines From Investors\n\nNEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt alerts investors in Grail,\nInc. (NASDAQ: GRAL) of a pending securities class action. Class Period: May\n13, 2025 through February 19, 2026. Check if you might be eligible to recover\nyour investment losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4732628-10&h=1501327374&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187609%26wire%3D4&a=Check+if+you+might+be+eligible+to+recover+your+investment+losses)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  | (888) SueWallSt.\n\nGRAL shares lost $51.32 per share, plunging 50.55% in a single trading session\nafter Grail admitted its NHS-Galleri trial failed to achieve its primary\nendpoint. The Court has set August 4, 2026 as the deadline to apply for lead\nplaintiff appointment.\n\nThe Alleged Data Withholding Strategy\n\nThe lawsuit asserts that throughout the Class Period, Grail's leadership\ndeliberately withheld detailed results from the NHS-Galleri trial's prevalent\nscreening round, citing the need to protect \"the integrity of the trial as a\nwhole.\" The action claims this justification masked a more troubling reality:\nthe concealed data allegedly contained trendlines suggesting the trial's\nthree-year screening duration was insufficient to demonstrate the primary\nendpoint of a statistically significant reduction in Stage III and IV cancers.\n\nWhen analysts pressed for specifics, management repeatedly deflected. On the\nQ1 2025 earnings call, executives confirmed the positive predictive value was\n\"substantially higher\" than 43% but stated: \"We're not sharing what that\nnumber is.\" As alleged, this selective disclosure pattern allowed the Company\nto promote favorable metrics while burying unfavorable signals about clinical\nutility.\n\nSelective Transparency in Multi-Cancer Early Detection\n\nThe securities action highlights a pattern common in diagnostic companies:\nsharing favorable test performance metrics while withholding clinical outcome\ndata that would temper investor enthusiasm.\n\n * Management promoted PPV, specificity (99.5%), and cancer signal of origin\naccuracy (88%) as evidence the test was \"working in the real world\"\n * The complaint alleges these metrics, while accurate in isolation, obscured the\ncritical question of whether Galleri could demonstrate a measurable reduction\nin late-stage cancer diagnoses\n * Defendants repeatedly cited \"safeguard[ing]\" participants and trial integrity\nas reasons for nondisclosure, the lawsuit contends\n * The Company acknowledged only after the trial failed that \"a longer follow-up\ntime\" was probably necessary\n * At no point during the Class Period did management disclose that internal\ntrendlines suggested the primary endpoint was at risk, as alleged in the\naction\n\"Investors deserve transparency about material risks that could affect their\ninvestments. When a company selectively discloses favorable screening metrics\nwhile withholding data about the achievability of a trial's primary clinical\nendpoint, shareholders cannot make informed decisions.\" -- Joseph E. Levi,\nEsq.\n\nLearn more about the case\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4732628-10&h=1922850621&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187609%26wire%3D4&a=Learn+more+about+the+case)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi\n& Korsinsky LLP has established itself as\na nationally-recognized securities litigation firm that has secured hundreds\nof millions of dollars for aggrieved shareholders and built a track\nrecord of winning high-stakes cases. The firm has\nextensive expertise representing investors in complex securities litigation\nand a team of over 70 employees to serve our clients. For seven years in a\nrow, Levi & Korsinsky has ranked in ISS Securities Class Action Services'\nTop 50 Report as one of the top securities litigation firms in the United\nStates.\n\nFrequently Asked Questions About the GRAL Lawsuit\n\nQ: Who is eligible to join the GRAL investor lawsuit? A: Investors who\npurchased GRAL stock or securities between May 13, 2025 and February 19, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: How much did GRAL stock drop? A: Shares fell approximately 50.55%, a\ndecline of $51.32 per share, after the company disclosed that the NHS-Galleri\ntrial's primary endpoint of statistically significant Stage III-IV cancer\nreduction was not observed. Investors who purchased shares during the class\nperiod at artificially inflated prices may be entitled to compensation.\n\nQ: What do GRAL investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my GRAL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html\n(https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2765490\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbNyhzna","title":"GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline","author":"PR Newswire","ticker":"GRAL","created":"2026-07-16T14:09:00.831Z","tickers":["GRAL"],"exchange":"NASDAQ","article_body":"GRAL DEADLINE: SueWallSt Reminds Grail, Inc. Investors of Upcoming Securities Class Action Deadline\n\nPR Newswire\n\nNEW YORK, July 16, 2026\n\nTime-Sensitive: Allegations Focus on Defendants' Refusal to Share Detailed\nNHS-Galleri Data, Potentially Concealing Adverse Trendlines From Investors\n\nNEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt alerts investors in Grail,\nInc. (NASDAQ: GRAL) of a pending securities class action. Class Period: May\n13, 2025 through February 19, 2026. Check if you might be eligible to recover\nyour investment losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4732628-10&h=1501327374&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187609%26wire%3D4&a=Check+if+you+might+be+eligible+to+recover+your+investment+losses)\n or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  | (888) SueWallSt.\n\nGRAL shares lost $51.32 per share, plunging 50.55% in a single trading session\nafter Grail admitted its NHS-Galleri trial failed to achieve its primary\nendpoint. The Court has set August 4, 2026 as the deadline to apply for lead\nplaintiff appointment.\n\nThe Alleged Data Withholding Strategy\n\nThe lawsuit asserts that throughout the Class Period, Grail's leadership\ndeliberately withheld detailed results from the NHS-Galleri trial's prevalent\nscreening round, citing the need to protect \"the integrity of the trial as a\nwhole.\" The action claims this justification masked a more troubling reality:\nthe concealed data allegedly contained trendlines suggesting the trial's\nthree-year screening duration was insufficient to demonstrate the primary\nendpoint of a statistically significant reduction in Stage III and IV cancers.\n\nWhen analysts pressed for specifics, management repeatedly deflected. On the\nQ1 2025 earnings call, executives confirmed the positive predictive value was\n\"substantially higher\" than 43% but stated: \"We're not sharing what that\nnumber is.\" As alleged, this selective disclosure pattern allowed the Company\nto promote favorable metrics while burying unfavorable signals about clinical\nutility.\n\nSelective Transparency in Multi-Cancer Early Detection\n\nThe securities action highlights a pattern common in diagnostic companies:\nsharing favorable test performance metrics while withholding clinical outcome\ndata that would temper investor enthusiasm.\n\n * Management promoted PPV, specificity (99.5%), and cancer signal of origin\naccuracy (88%) as evidence the test was \"working in the real world\"\n * The complaint alleges these metrics, while accurate in isolation, obscured the\ncritical question of whether Galleri could demonstrate a measurable reduction\nin late-stage cancer diagnoses\n * Defendants repeatedly cited \"safeguard[ing]\" participants and trial integrity\nas reasons for nondisclosure, the lawsuit contends\n * The Company acknowledged only after the trial failed that \"a longer follow-up\ntime\" was probably necessary\n * At no point during the Class Period did management disclose that internal\ntrendlines suggested the primary endpoint was at risk, as alleged in the\naction\n\"Investors deserve transparency about material risks that could affect their\ninvestments. When a company selectively discloses favorable screening metrics\nwhile withholding data about the achievability of a trial's primary clinical\nendpoint, shareholders cannot make informed decisions.\" -- Joseph E. Levi,\nEsq.\n\nLearn more about the case\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4732628-10&h=1922850621&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fgrail-inc-class-action-lawsuit-gral%3Fprid%3D187609%26wire%3D4&a=Learn+more+about+the+case)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi\n& Korsinsky LLP has established itself as\na nationally-recognized securities litigation firm that has secured hundreds\nof millions of dollars for aggrieved shareholders and built a track\nrecord of winning high-stakes cases. The firm has\nextensive expertise representing investors in complex securities litigation\nand a team of over 70 employees to serve our clients. For seven years in a\nrow, Levi & Korsinsky has ranked in ISS Securities Class Action Services'\nTop 50 Report as one of the top securities litigation firms in the United\nStates.\n\nFrequently Asked Questions About the GRAL Lawsuit\n\nQ: Who is eligible to join the GRAL investor lawsuit? A: Investors who\npurchased GRAL stock or securities between May 13, 2025 and February 19, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses, not on whether you still hold the shares.\n\nQ: How much did GRAL stock drop? A: Shares fell approximately 50.55%, a\ndecline of $51.32 per share, after the company disclosed that the NHS-Galleri\ntrial's primary endpoint of statistically significant Stage III-IV cancer\nreduction was not observed. Investors who purchased shares during the class\nperiod at artificially inflated prices may be entitled to compensation.\n\nQ: What do GRAL investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my GRAL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html\n(https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2765490\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-16T14:09:00.908475555Z","server_sent_at_ms":1784210940908},"received_at":"2026-07-16T14:09:00.974Z","source_url":"https://www.prnewswire.com/news-releases/gral-deadline-suewallst-reminds-grail-inc-investors-of-upcoming-securities-class-action-deadline-302827273.html"},"analysis":{"id":"79734","press_release_id":"90686","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky, issued a solicitation notice reminding Grail, Inc. investors of the August 4, 2026 lead plaintiff deadline in a pending class action.\n\nThe complaint alleges Grail withheld unfavorable data regarding its NHS-Galleri trial while promoting positive metrics, leading to a reported 50.55% share price drop.\n\nThis is a standard law-firm marketing communication; no new material disclosures have been made by the company regarding the lawsuit status.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"Investors deserve transparency about material risks that could affect their investments. When a company selectively discloses favorable screening metrics while withholding data about the achievability of a trial's primary clinical endpoint, shareholders cannot make informed decisions.","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"}],"products":["Galleri","NHS-Galleri"],"companies":[{"name":"Grail, Inc.","ticker":"GRAL"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$51.32","context":"per share loss mentioned in solicitation"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by SueWallSt/Levi & Korsinsky. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GRAL"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky, issued a solicitation notice reminding Grail, Inc. investors of the August 4, 2026 lead plaintiff deadline in a pending class action.\n\nThe complaint alleges Grail withheld unfavorable data regarding its NHS-Galleri trial while promoting positive metrics, leading to a reported 50.55% share price drop.\n\nThis is a standard law-firm marketing communication; no new material disclosures have been made by the company regarding the lawsuit status.","key_figures":null,"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"}],"products":["Galleri","NHS-Galleri"],"companies":[{"name":"Grail, Inc.","ticker":"GRAL"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$51.32","context":"per share loss mentioned in solicitation"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-16T17:58:41.982Z","global_importance":15,"audience_relevance":15,"importance_components":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":73981,"modelName":"glm-4.7"}}